Prostate carcinoma: Opportunities for translational research

Journal of Cellular Biochemistry

Volumn 91, Issue 3, 2004, Pages 433-442

  Fitzgerald, T J ^a   Simon, Edmund ^a   Meyer, Joshua ^b  

^a Department of Radiation Oncology ^*  (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Prostate carcinoma; Radiation oncology; Surgery

Indexed keywords

AMIFOSTINE; ANTIOXIDANT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; KERATINOCYTE GROWTH FACTOR; NITROXIDE; TELOMERASE; VANDETANIB; VASCULOTROPIN RECEPTOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTATE SPECIFIC ANTIGEN; PTGS2 PROTEIN, HUMAN; VASCULOTROPIN A;

CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CELL ADHESION; CELL KILLING; CELL SURVIVAL; DNA REPAIR; ENZYME ACTIVITY; GINSENG; HIGH RISK PATIENT; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; BLOOD; BRACHYTHERAPY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG THERAPY; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; RECURRENT DISEASE;

PANAX GINSENG;

BRACHYTHERAPY; CYCLOOXYGENASE 2; DIAGNOSTIC IMAGING; DRUG THERAPY; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3843061618     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10693     Document Type: Review

References (68)

1. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrajanen K, Kosma VM. 1999. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer 80:477-482.
2. Abdollahi A, Lipson KE, Han X, et al. 2003. SU5416 and SU6668 attenuate the angiogenic effects of radiation induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63:3755.
3. Aus G, Abrahamsson PA, Ahlgren G, et al. 1998. Hormonal treatment before radical prostatectomy: Three year follow up. J Urol 159:2013.
4. Bolla M, Gonzalez D, Warde P, et al. 1997. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goselin. New Eng J Med 337:295-300.
5. Brachman DG, Thomas T, Hilbe J, Beyer D. 2000. Failure free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48:111.
6. Carter HB, Partin AW, et al. 2002. Diagnosis and staging of prostate cancer. In: Walsh PC, Retik AB, Vaughn ED, editors. Campbell's urology, eighth edition. New York: Elsevier Science. 3055 p.
7. Catalona WJ, Smith DS, Ratliff TL, et al. 1993. Detection of organ confined prostate cancer is increased through prostate specific antigen based screening. JAMA 270:948.
8. Cheing GC, Chein MH, Whittington R, et al. 2003. Clinical utility of endorectal MRI in determinig PSA outcome for patients with biopsy gleason score 7, PSA < 10, and clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 55:64.
9. Chism DB, Horwitz EM, Hanlon AL, et al. 2003. Late morbidity profiles in prostate cancer patients treated to 79-84 GY by a simple four field co-planar technique. Int J Radiat Oncol Biol Phys 55:71.
10. Coleman CN, Blakely WE, Fike JR, et al. 2003. Molecular and cellular biology of moderate dose (1-10 Gy) radiation and potential mechanisms of radiation protection: Report of a workshop at Bethesda MD, Dec 17-18, 2001. Radiate Res 159:812.
11. Cordes N, van Beuningen D. 2003. Cell adhesion to the extracellular matrix protein fibronectin modulates radiation dependant G2 arrest involving integrin linked kinase and gylcogen synthase kinase. Br J Cancer 88:1470.
12. Corn BW, Hanks GE, Schultheis TE, et al. 1995. Conformal treatment of prostate cancer with improved targeting: Superior prostate specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys 32:325.
13. D'Amico AV, Schnall M, Whitington R, et al. 1998. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 51:449.
14. D'Amico AV, Renshaw AA, Aresenault L, et al. 1999. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: Potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys 45:841.
15. Dalkin BL, Ahman FR, Nagle R, et al. 1996. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol 155:1357.
16. Dent P, Yacoub A, Contessa J, et al. 2003. Stress and radiation induced activation of multiple intracellular signaling pathways. Radiat Res 159:283.
17. Despras E, Miccoli L, Creminon C, et al. 2003. Depletion of K1N17, a human DNA replication protein, increases radiosensitivity of RKO cells. Radiat Res 159:748.
18. Dong L, Antolak J, Salepour M, et al. 2003. Patient specific point dose measurement for IMRT minitor unit verification. Int J Radiat Oncol Phys 56:867.
19. Doyle J, Li YQ, Salloum A, et al. 1996. The effects of radiation on neo-vascularization in a rat model. Plas Recon Surg 98(1):129.
20. Epstein JL. 1990. Evaluation of radical prostatectomy margins designated as negative, closely approaching, and positive. Am J Surg Path 14:626.
21. Epstein JI, Carmichael MJ, Pizov G, et al. 1993a. Influence of capsular penetration on progression following radical prostatectomy: A study of 196 cases with long term follow up. J Urol 150:135.
22. Epstein JI, Pizov G, Walsh PC. 1993b. Correlation of pathologic findings with progression after radical prostatectomy. Cancer 71:3582.
23. Folkman J. 1990. What is the evidence that tumors are angiogenesis dependant? J Nat Can Inst 82:4.
24. Fornaro M, Manes T, Languino L. 2001. Integrins and prostate cancer metastasis. Cancer Metastasis Rev 20:321.
25. Fujita H, Koshida K, Keller ET, et al. 2002. Cylooxygenase-2 promotes prostate cancer progression. Prostate 53:232.
26. Gaillo O, Masini E, Morbidelli L, et al. 1998. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Nat Can Inst 90:587.
27. Goluboff ET, Prager D, Rukstalis D, et al. 2001. Safety and efficacy of exisulind for treatment of recurrent prostate carcinoma following radical prostatectomy. J Urol 166:882.
28. Greenlee RT, Hill-Harmon MB, Murray T, et al. 2001. Cancer statistics, Cancer J Clin 51:15.
29. Gupta AK, Cerniglia GJ, Mick MS, et al. 2003. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56:846.
30. Hanks GE, Krall JM, Hanlon AL, et al. 1994. Patterns of care and RTOG studies in prostate cancer: Long term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 28:39.
31. Hurdes GR, Nathan F, Khater C, et al. 1997. Phase 2 trial of 96 hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer. J Clin One 15:3156.
32. Khan MA, Partin AW. 2003. Management of high-risk populations with locally advanced prostate carcinoma. The Oncologist 8:259.
33. Kirschenbaum A, Liu X, Yao S, Levine AC. 2001. The role of cyclooxygenase-2 in prostate cancer. Urology 58(Suppl 2A):127.
34. Klotz LH, Herr HW, Morse MJ, Whitmore WF. 1986. Intermittent endocrine therapy for advanced prostate carcinoma. Cancer 58:2546.
35. Kreis W, Budman DR, Fetten J, et al. 1999. Phase 1 trial of the combination of daily estramustine and low dose hydrocortisone in men with hormone refractory prostate cancer. Preliminary results of cancer and leukemia group B trial 9780. Sem One 26:39.
36. Lerner SE, Blute ML, Zincke H. 1995. Extended experience with radical prostatectomy for clinical T3 prostate cancer: Outcome and contemporary morbidity. J Urol 154:374.
37. Lewis J, Truong T, Schwartz M. 2002. Integrins regulate the apoptotic response to DNA damage through modulation of p53. PNAS 99(6):3627.
38. Lin Y, Urema H, Fujinami K, et al. 1997. Telomerase activity in primary prostate cancer. J Urol 157:1161.
39. Liu X, Kirschenbaum A, Yao S, et al. 1999. Upregulation of vascular endothelial growth factor by cobalt chloride simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in metastatic human prostate cancer cell line. Clin Exp Metastasis 17(8):687.
40. Liu X, Kirschenbaum A, Yao S, et al. 2000. Inhibition of cyclooxygenase-2 suppresses angiogenesis and growth of prostate cancer in vivo. J Urol 164:820.
41. Manyak MJ, Hinkle GH, Olsen JO, et al. 1999. Immunoscintigraphy with indium-111capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer. Urology 54:1058.
42. Marx J. 2003. A boost for tumor starvation. Science 301:452.
43. Michalski J, Winter K, Purdy J, et al. 2003. Preliminary evaluation of low grade toxicity with conformal radiation therapy for prostate cancer on RTOG dose levels I and II. Int J Radiat Oncol Biol Phys 56:192.
44. Oh WK, Kantoff P. 1998. Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 160:1220.
45. Oh WK, Halabi S, Kelly WK, et al. 2002. A phase 2 study of estramustine, docetaxel, and carboplatin with G-CSF support in men with hormone refractory prostate cancer, CALGB 99813. Proc Am Soc Clin One 21:195a.
46. Partin AW, Piantadosi S, Sanda S, et al. 1995. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45:831.
47. Partin AW, Kattan MW, Subong EN, et al. 1997. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate carcinoma. A multi-institutional update. JAMA 277:1445.
48. Petrylak DP, Macarthur RB, O'Connor J, et al. 1999. Phase 1 trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17(3):958.
49. Pilepich MV, Krall JM, al-Sarraf M, et al. 1995. Androgen deprivation with radiation therapy alone for locally advanced prostate carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616.
50. Pilepich MV, Caplan R, Byhardt RW, et al. 1997. Phase 3 trial of androgen supression using goselin in unfavorable prognosis carcinoma of the prostate treated with definitive radioterapy: Report of the Radiation Therapy Oncology Group Protocol 85-31. J Clin One 15:1013.
51. Potters L, Purrazzella R, Brustein S, et al. 2003. The prognostic significance of gleason grade in patients treated with permanent brachytherapy. Int J Radiat Oncol Biol Phys 56:749.
52. Pound CR, Partin AW, Epstein JL, et al. 1997. Prostate specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24:395.
53. Ryu J, Winter K, Michalski J, et al. 2002. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 54:1036.
54. Savarese DM, Halabi S, Hars V, et al. 2001. Phase 2 study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: A final report of CALGB 9780, Cancer and Leukemia Group B. J Clin Oncol 19:2509.
55. Schulman CC, Debruyne FM, Forster G, et al. 2000. Four year follow up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3 N0 M0 prostate cancer: European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38:706.
56. See WA, Wirth MP, McLeod DG, et al. 2002. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 168:429.
57. Sethi A, Mohideen N, Leybovich L, Mulhall J. 2003. Role of IMRT in reducing penile doses in dose escalation prostate cancer. Int J Radiat Oncol Biol Phys 55:970.
58. Song JY, Han SK, Bae KG, et al. 2003. Radioprotective effects of ginsan, an immunomodulator. Radiat Res 159:768.
59. Southwick PC, Catalona WJ, Partin AW, et al. 1999. Prediction of post radical prostatectomy pathological outcome for stage Tie prostate cancer with percent free prostate specific antigen: A prospective multi center trial. J Urol 162:1346.
60. Stamey TA, McNeil JE, Yemoto CM, et al. 1999. Biological determinants of cancer progression in men with prostate carcinoma. JAMA 281:1395.
61. Straub B, Muller M, Krause H, et al. 2001. Molecular staging of surgical margins after radical prostatectomy by detection of telomerase activity. Prostate 49:140.
62. Terris MK, McNeal JE, Freiha FS, et al. 1993. Efficacy of trans rectal ultrasound guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J Urol 149:1035.
63. Thompson IM, Goodman PJ, Tangen CM, et al. 2003. The influence of finasteride on the development of prostate cancer. New Eng J Med 349(3):213.
64. Trachtenberg J. 1987. Experimental treatment of prostate cancer by intermittant hormonal therapy. J Urol 137:785.
65. Uotila P, Valve E, Martikainen P, et al. 2001. Increased expression of cyclooxygenase-2 and nitric oxide synthetase-2 in human prostate cancer. Urol Res 29:25.
66. Yacoub A, McKinstry R, Hinman D, et al. 2003. Epidermal growth factor and ionizing radiation up-regulate the DNA repair gene XRCC1 and ERCC1 in DU 145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 158:439.
67. Zelefsky MJ, Yamada Y, Marion C, et al. 2003. Improved conformality and decreased toxicity with intraoperative computer optimized transperineal ultrasound guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 55:956.
68. Ziche M, Morbidelli L, Choudhuri R, et al. 1997. Nitric oxide synthase lies downstream from vascular endothelial growth factor induced but not basic fibroblast growth factor induced angiogenesis. J Clin Invest 99(11):2625.